Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.60
FGEN's Cash-to-Debt is ranked lower than
69% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. FGEN: 2.60 )
Ranked among companies with meaningful Cash-to-Debt only.
FGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: 1.86 Max: 2.6
Current: 2.6
0.43
2.6
Equity-to-Asset 0.33
FGEN's Equity-to-Asset is ranked lower than
81% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. FGEN: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
FGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.33 Max: 0.46
Current: 0.33
-0.3
0.46
Piotroski F-Score: 5
Altman Z-Score: 2.20
Beneish M-Score: -3.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -29.88
FGEN's Operating Margin % is ranked higher than
61% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. FGEN: -29.88 )
Ranked among companies with meaningful Operating Margin % only.
FGEN' s Operating Margin % Range Over the Past 10 Years
Min: -42.93  Med: -36.41 Max: -7.78
Current: -29.88
-42.93
-7.78
Net Margin % -34.35
FGEN's Net Margin % is ranked higher than
59% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. FGEN: -34.35 )
Ranked among companies with meaningful Net Margin % only.
FGEN' s Net Margin % Range Over the Past 10 Years
Min: -49.4  Med: -43.24 Max: -14.63
Current: -34.35
-49.4
-14.63
ROE % -35.79
FGEN's ROE % is ranked higher than
53% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. FGEN: -35.79 )
Ranked among companies with meaningful ROE % only.
FGEN' s ROE % Range Over the Past 10 Years
Min: -89.68  Med: -43 Max: -35.79
Current: -35.79
-89.68
-35.79
ROA % -13.02
FGEN's ROA % is ranked higher than
67% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. FGEN: -13.02 )
Ranked among companies with meaningful ROA % only.
FGEN' s ROA % Range Over the Past 10 Years
Min: -17.98  Med: -13.12 Max: -5.31
Current: -13.02
-17.98
-5.31
ROC (Joel Greenblatt) % -40.41
FGEN's ROC (Joel Greenblatt) % is ranked higher than
70% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. FGEN: -40.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57.05  Med: -36.93 Max: -3.35
Current: -40.41
-57.05
-3.35
GuruFocus has detected 3 Warning Signs with FibroGen Inc $FGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FGEN Guru Trades in Q1 2016

Paul Tudor Jones 19,593 sh (New)
Joel Greenblatt Sold Out
» More
Q2 2016

FGEN Guru Trades in Q2 2016

Paul Tudor Jones 10,993 sh (-43.89%)
» More
Q3 2016

FGEN Guru Trades in Q3 2016

Jim Simons 223,300 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FGEN Guru Trades in Q4 2016

Joel Greenblatt 21,899 sh (New)
Paul Tudor Jones 17,575 sh (New)
Jim Simons 332,600 sh (+48.95%)
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:SOLTF, NAS:ARRY, NAS:SRPT, NAS:ONCE, OTCPK:MPSYY, NAS:AAAP, NAS:LXRX, NYSE:AXON, NAS:PBYI, NAS:GBT, NAS:BPMC, NYSE:CBM, NAS:BGNE, OTCPK:DBVTF, NAS:DERM, NAS:HALO, NAS:INVA, NAS:TBPH, OTCPK:GENSF, OTCPK:AKBLF » details
Traded in other countries:1FG.Germany, FGEN.Mexico,
FibroGen Inc is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.

FibroGen is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Ratios

vs
industry
vs
history
PB Ratio 10.13
FGEN's PB Ratio is ranked lower than
85% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. FGEN: 10.13 )
Ranked among companies with meaningful PB Ratio only.
FGEN' s PB Ratio Range Over the Past 10 Years
Min: 4.36  Med: 7.33 Max: 10.81
Current: 10.13
4.36
10.81
PS Ratio 9.05
FGEN's PS Ratio is ranked higher than
61% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. FGEN: 9.05 )
Ranked among companies with meaningful PS Ratio only.
FGEN' s PS Ratio Range Over the Past 10 Years
Min: 5.38  Med: 7.69 Max: 11.24
Current: 9.05
5.38
11.24
Price-to-Free-Cash-Flow 918.50
FGEN's Price-to-Free-Cash-Flow is ranked lower than
97% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. FGEN: 918.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
FGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 757.41  Med: 881.48 Max: 979.63
Current: 918.5
757.41
979.63
Price-to-Operating-Cash-Flow 551.13
FGEN's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. FGEN: 551.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
FGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 454.44  Med: 528.89 Max: 587.78
Current: 551.13
454.44
587.78
Current Ratio 4.09
FGEN's Current Ratio is ranked higher than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. FGEN: 4.09 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.16 Max: 4.09
Current: 4.09
2.23
4.09
Quick Ratio 4.09
FGEN's Quick Ratio is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. FGEN: 4.09 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.16 Max: 4.09
Current: 4.09
2.23
4.09
Days Sales Outstanding 21.24
FGEN's Days Sales Outstanding is ranked higher than
81% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. FGEN: 21.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.24  Med: 35.69 Max: 48.63
Current: 21.24
21.24
48.63

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.12
FGEN's Price-to-Tangible-Book is ranked lower than
78% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. FGEN: 10.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.29  Med: 8.74 Max: 10.64
Current: 10.12
7.29
10.64
Price-to-Median-PS-Value 1.18
FGEN's Price-to-Median-PS-Value is ranked lower than
59% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. FGEN: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.02  Med: 1.05 Max: 1.44
Current: 1.18
1.02
1.44
Earnings Yield (Greenblatt) % -3.55
FGEN's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. FGEN: -3.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -276.72  Med: 0 Max: 0
Current: -3.55
-276.72
0

More Statistics

Revenue (TTM) (Mil) $179.6
EPS (TTM) $ -1.02
Short Percentage of Float4.38%
52-Week Range $14.50 - 27.30
Shares Outstanding (Mil)63.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 151 271 421
EPS ($) -1.85 -0.89 0.34
EPS without NRI ($) -1.85 -0.89 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : March 23, 2017 Mar 23 2017
FIBROGEN INC Financials Mar 07 2017
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
FIBROGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 02 2017
Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT Mar 02 2017
FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 01 2017
FibroGen Reports Fiscal 2016 Financial Results Mar 01 2017
Q4 2016 FibroGen Inc Earnings Release - After Market Close Mar 01 2017
FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017 Feb 22 2017
FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 16 2017
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing... Feb 03 2017
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017 Jan 31 2017
Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen Jan 30 2017
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6% Jan 30 2017
FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 30 2017
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Jan 30 2017
FibroGen (FGEN) Shares March Higher, Can It Continue? Jan 23 2017
Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers... Jan 20 2017
Here Are Two Market Moving Biotech Catalysts To Watch This Week Jan 17 2017
6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)